Indo-Bangla Pharmaceuticals Limited experienced a significant 91.65% decrease in profit, amounting to Tk 11.62 lakh, during the third quarter of the current financial year. In comparison, the company had earned a profit of Tk 1.39 crore in the same quarter of the previous year, 2021-22. The unaudited financial statements reveal that the earnings per share (EPS) for January-March 2022-23 stood at Tk 0.01, as opposed to Tk 0.12 in the corresponding quarter of 2021-22.
For the cumulative period of July-March in FY23, Indo-Bangla Pharmaceuticals’ profit amounted to Tk 1.16 crore, marking an 83% decline from the Tk 7.20 crore reported in the same period of FY22. Consequently, the EPS dropped to Tk 0.10 from Tk 0.62.
The company’s shares on the Dhaka Stock Exchange remained steady at Tk 17 in the latest trading session, maintaining the same value as the previous session.